Other content in this Stream
Liminal BioSciences announces key appointment to its leadership team
LMNL announced today the addition of Moira Daniels as the new Head of Regulatory Affairs and Quality Assurance, to its senior leadership team.
Liminal BioSciences presents new preclinical data on PBI-4050 and NASH candidate PBI-4547
Liminal BioSciences reports its 2019 third quarter financial results and business highlights
Liminal BioSciences to report Q3 2019 results and hold conference call
Annual Report 2018
2018 was once again a year filled with strong scientific and clinical program development achievements for Prometic.
Quarterly Report 2018 Q3
Successful Type C meeting with FDA: agreement on proposed plan of action for RyplazimTM (plasminogen) manufacturing process along with Substantial reduction in R&D costs of up to $30 million.
Quarterly Report Q2 2018
Advanced multiple initiatives aimed at extending cash runway, including ongoing partnering discussions related to both PBI-4050 and RyplazimTM (plasminogen).
Board of Directors Charter 2019
Code of Ethics and Business Conduct 2019
Position Description Lead Independent Director 2019
Liminal BioSciences Articles of Incorporation 2019
Prometic Life Sciences Inc. articles of incorporation and articles of amendments
Plasminogen Replacement Therapy for Congenital Plasminogen Deficiency
At Prometic Life Sciences we are committed to addressing unmet medical needs in rare diseases such as Congenital Plasminogen Deficiency (PLGD).
Virtual Tour of Prometic Life Science's Manufacturing Process
You will discover how our industry leading technology is now being used to extract and purify therapeutic proteins from human plasma to provide for the development of best in class products.
Joe Parker, MD: PBI-4050 Demonstrates Promising Efficacy Results for IPF Treatment